Loading
The freshest signals in cancer: new papers, trial results, approvals and law, updated with every build.
Ranked newest first, with approvals, withdrawals and phase 3 results counting as two weeks fresher than their date, other results, law and papers in the leading journals one week fresher, and preprints one week older; every kind keeps its most recent items so no filter is empty while its source has data. Within a day the weightier items come first. Pick types to combine them; For you narrows to the cancer chosen in For me (a choice that stays in this browser); the first filter reads the full 500-item feed.
200 items on this page.
637 changelog entries, 1 regulatory event, 1 upcoming date, 4 corrections.
567 changelog entries, 1 regulatory event, 1 upcoming date, 4 corrections.
491 changelog entries, 1 regulatory event, 1 upcoming date, 2 corrections.
Published in Nat Med on 22 September 2026; found by the roadmap watch for PATHFINDER 2.
451 changelog entries, 1 regulatory event, 2 upcoming dates, 2 corrections.
Published in J Pediatr Endocrinol Metab on 22 September 2026; matched the OnCo record for Paediatric low-grade glioma.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched CAR-T cell therapy and Aldesleukin.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched Single-cell & spatial profiling.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched CAR-T cell therapy and Aldesleukin.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched Fulvestrant, HER3 and AKT.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched RNA sequencing & expression profiling, BRCA1 / BRCA2 and Long-read sequencing.
Posted on Research Square on 22 September 2026; not peer reviewed; matched Atlas.
Posted on Research Square on 22 September 2026; not peer reviewed; matched MET.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched ATR.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched GD2, Bispecific antibodies and Antibody-drug conjugate.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched PARP inhibitors, PARP and BRCA1 / BRCA2.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched CSF1R.
Posted on Research Square on 22 September 2026; not peer reviewed; matched Liquid biopsy.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched PARP inhibitors, PARP and ATR.
Posted on Research Square on 22 September 2026; not peer reviewed; matched AI trial matching & clinical decision support and BioEmu.
Posted on Research Square on 22 September 2026; not peer reviewed; matched Chemoprevention & risk-reducing surgery.
Published in Blood Cancer Discov on 21 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.
Published on 21 September 2026 after first appearing as a preprint; matched Platinum agents and Androgen receptor.
Published in Muscle Nerve on 21 September 2026; matched the OnCo record for Small intestine cancer.
Published on 21 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.
Published in Pediatr Blood Cancer on 21 September 2026; matched the OnCo record for Acute myeloid leukaemia in children.
Published on 21 September 2026 after first appearing as a preprint; matched Med-Gemini and MedLM and State.
Published in Cancer Immunol Res on 21 September 2026; matched the OnCo record for TCR-T cell therapy.
Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for Aumolertinib.
Published in Genet Test Mol Biomarkers on 21 September 2026; matched the OnCo record for CYP17A1.
Published on 21 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.
310 changelog entries, 1 upcoming date, 7 publications, 2 corrections.
Published in Arthritis Care Res (Hoboken) on 21 September 2026; matched the OnCo record for Tocilizumab.
Published in Adv Sci (Weinh) on 21 September 2026; matched the OnCo record for Floxuridine.
Published in Clin Cancer Res on 21 September 2026; matched the OnCo record for Adavosertib.
Published in Br J Dermatol on 21 September 2026; matched the OnCo record for Mogamulizumab.
Published in Head Neck on 21 September 2026; matched the OnCo record for Toripalimab.
Published in Arthritis Rheumatol on 21 September 2026; matched the OnCo record for Emapalumab.
Published in Lab Anim Res on 20 September 2026; matched the OnCo record for Genetically engineered mouse models.
Published in Oncogene on 20 September 2026; matched the OnCo record for Humanised mouse models.
Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Oncotype DX.
Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Penile cancer.
Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Belzutifan.
Published in Cardiovasc Toxicol on 20 September 2026; matched the OnCo record for HER4.
Published in Br J Haematol on 20 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.
Published in Acta Biomater on 20 September 2026; matched the OnCo record for CD123.
Published in Int J Cancer on 20 September 2026; matched the OnCo record for CAPOX.
Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Multi-cancer early detection.
Published in Expert Opin Ther Pat on 20 September 2026; matched the OnCo record for Avutometinib + defactinib.
Published in Future Oncol on 20 September 2026; matched the OnCo record for Avelumab.
Published in Clin Med (Lond) on 20 September 2026; matched the OnCo record for Tumour treating fields.
Published on 19 September 2026 after first appearing as a preprint; matched Atlas.
Published in Bioorg Chem on 19 September 2026; matched the OnCo record for Vinblastine.
Published in J Hematop on 19 September 2026; matched the OnCo record for CD123.
Published on 19 September 2026 after first appearing as a preprint; matched STAT5.
Published in Curr Opin Oncol on 19 September 2026; matched the OnCo record for Talazoparib.
Published in EJHaem on 19 September 2026; matched the OnCo record for BCR::ABL1.
Published in Mol Ther on 19 September 2026; matched the OnCo record for Plerixafor.
Published in BMJ Paediatr Open on 19 September 2026; matched the OnCo record for HB-200.
Published in Radiother Oncol on 19 September 2026; matched the OnCo record for Limited-stage small-cell lung cancer.
Published on 19 September 2026 after first appearing as a preprint; matched Estrogen receptor.
Published in Eur J Nucl Med Mol Imaging on 19 September 2026; matched the OnCo record for Gallium-68 gozetotide.
Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for Grade 3 well-differentiated neuroendocrine tumour.
Published in Cell Death Discov on 19 September 2026; matched the OnCo record for Lutetium-177 dotatate.
Published in Biochem Pharmacol on 19 September 2026; matched the OnCo record for In vivo CAR-T.
Published in Libyan J Med on 19 September 2026; matched the OnCo record for Anal high-grade squamous intraepithelial lesions.
Published in Oral Oncol on 19 September 2026; matched the OnCo record for Transoral robotic surgery.
Published in Biochem Pharmacol on 19 September 2026; matched the OnCo record for Acute promyelocytic leukaemia.
Published in Cancer Metastasis Rev on 19 September 2026; matched the OnCo record for Ripretinib.
Published in Transplant Cell Ther on 19 September 2026; matched the OnCo record for CD33.
Published in Clin Drug Investig on 19 September 2026; matched the OnCo record for Bendamustine.
Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for Salivary duct carcinoma.
Published in Int J Hematol on 19 September 2026; matched the OnCo record for Decitabine.
Published in Target Oncol on 19 September 2026; matched the OnCo record for Tucatinib.
Published in Int J Clin Oncol on 19 September 2026; matched the OnCo record for Amrubicin.
Published in J Robot Surg on 19 September 2026; matched the OnCo record for Transoral robotic surgery.
On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Published in J Clin Oncol on 18 September 2026; matched the OnCo record for Early-stage classical Hodgkin lymphoma.
Published in Cancer Discov on 18 September 2026; matched the OnCo record for Amivantamab.
Published in Cancer Cell on 18 September 2026; matched the OnCo record for Zoledronic acid.
Published in Oncol Rep on 18 September 2026; matched the OnCo record for DNMT1.
Published in Dermatologie (Heidelb) on 18 September 2026; matched the OnCo record for Metastatic and recurrent anal squamous cell carcinoma.
Published in Oncogene on 18 September 2026; matched the OnCo record for Genetically engineered mouse models.
Published in Mol Med Rep on 18 September 2026; matched the OnCo record for EGFR-mutated non-small-cell lung cancer.
Published in Br J Haematol on 18 September 2026; matched the OnCo record for Avelumab.
Published in Clin Oncol (R Coll Radiol) on 18 September 2026; matched the OnCo record for Hypopharyngeal cancer.
Published in Mol Cell Proteomics on 18 September 2026; matched the OnCo record for Anagrelide.
Published in J Clin Pathol on 18 September 2026; matched the OnCo record for Paige Prostate Detect.
Published in Spine J on 18 September 2026; matched the OnCo record for Chordoma.
Published in BMJ Open on 18 September 2026; matched the OnCo record for Gallium-68 gozetotide.
Published in Angew Chem Int Ed Engl on 18 September 2026; matched the OnCo record for CD22.
Published in J Urol on 18 September 2026; matched the OnCo record for Testicular germ cell tumours.
Published in Cell Rep Med on 18 September 2026; matched the OnCo record for Pathology & radiology foundation models.
Published in Int J Surg Pathol on 18 September 2026; matched the OnCo record for VENTANA PD-L1 (SP263) Assay.
Published in Am J Clin Oncol on 18 September 2026; matched the OnCo record for Rivoceranib.
Published in Patient on 18 September 2026; matched the OnCo record for Vimseltinib.
Published in J Am Acad Dermatol on 18 September 2026; matched the OnCo record for Skin cancer screening.
Published in Cancer Res Commun on 18 September 2026; matched the OnCo record for Ampullary cancer.
Published on 18 September 2026 after first appearing as a preprint; matched Nintedanib and Immune checkpoint inhibitors.
Published in BMJ Case Rep on 18 September 2026; matched the OnCo record for Cladribine.
Published in Ann Med on 18 September 2026; matched the OnCo record for Stage III melanoma.
Published in Urol Oncol on 18 September 2026; matched the OnCo record for Gemcitabine + cisplatin.
Published in J Neurooncol on 18 September 2026; matched the OnCo record for Paediatric low-grade glioma.
Published in Curr Opin Oncol on 18 September 2026; matched the OnCo record for Vorasidenib.
Published in Actas Dermosifiliogr on 18 September 2026; matched the OnCo record for Mogamulizumab.
Published on 18 September 2026 after first appearing as a preprint; matched State.
Published in BMC Med Imaging on 18 September 2026; matched the OnCo record for Locally advanced cervical cancer.
Published in Phys Med on 18 September 2026; matched the OnCo record for MR-guided adaptive radiotherapy.
Published in J Immunother Cancer on 18 September 2026; matched the OnCo record for Imaging mass cytometry.
Published in J Immunother Cancer on 18 September 2026; matched the OnCo record for Ciltacabtagene autoleucel.
Published in J Comp Eff Res on 18 September 2026; matched the OnCo record for Small intestine cancer.
Published in Blood Adv on 18 September 2026; matched the OnCo record for Allogeneic stem cell transplantation.
Published on 18 September 2026 after first appearing as a preprint; matched Bevacizumab, Bevacizumab and Anti-angiogenic therapy.
Published in Future Oncol on 18 September 2026; matched the OnCo record for Node-positive and metastatic penile cancer.
Published in Structure on 18 September 2026; matched the OnCo record for HER3.
Published in Curr Hematol Malig Rep on 18 September 2026; matched the OnCo record for Ropeginterferon alfa-2b.
Published in Auris Nasus Larynx on 18 September 2026; matched the OnCo record for Companion diagnostics.
Published in J Comput Assist Tomogr on 18 September 2026; matched the OnCo record for Whole-body MRI.
Published in Mol Biol Rep on 18 September 2026; matched the OnCo record for CRAF.
Published in Drug Resist Updat on 18 September 2026; matched the OnCo record for Pazopanib.
303 changelog entries, 1 upcoming date, 11 publications, 8 corrections.
Published in Asian J Androl on 18 September 2026; matched the OnCo record for Onvansertib.
Published in ACS Sens on 18 September 2026; matched the OnCo record for Mesothelin.
Published in Oncol Rep on 18 September 2026; matched the OnCo record for Pemetrexed.
Published in J Enzyme Inhib Med Chem on 18 September 2026; matched the OnCo record for PARP.
Published in Cancer Lett on 18 September 2026; matched the OnCo record for cfDNA fragmentomics.
Published in Diagnosis (Berl) on 18 September 2026; matched the OnCo record for CEACAM5.
Published in Mol Cell Proteomics on 18 September 2026; matched the OnCo record for Malignant peripheral nerve sheath tumour.
Published in J Formos Med Assoc on 18 September 2026; matched the OnCo record for Oral tongue and floor of mouth cancer.
Published on 18 September 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing.
Published in J Geriatr Oncol on 18 September 2026; matched the OnCo record for Geriatric assessment.
Published in Ann Surg Oncol on 18 September 2026; matched the OnCo record for Ampullary cancer.
Published in Mol Genet Genomics on 18 September 2026; matched the OnCo record for Elongation factor 2.
Published in Biochim Biophys Acta Gen Subj on 18 September 2026; matched the OnCo record for Smoothened.
Published in Curr Probl Cancer on 18 September 2026; matched the OnCo record for Teclistamab.
Published on 18 September 2026 after first appearing as a preprint; matched Cytarabine, Dacarbazine and Daunorubicin.
Published on 18 September 2026 after first appearing as a preprint; matched Decitabine + cedazuridine.
Published in Mol Cancer Ther on 18 September 2026; matched the OnCo record for MDM2 inhibitors.
Published in J Natl Compr Canc Netw on 18 September 2026; matched the OnCo record for Adagrasib.
Published in Science on 17 September 2026; matched the OnCo record for RaDaR.
Published in Cancer Discov on 17 September 2026; matched the OnCo record for YL201.
Published in Nat Med on 17 September 2026; matched the OnCo record for Diffuse midline glioma, H3 K27-altered.
Published in Ann Oncol on 17 September 2026; matched the OnCo record for Goserelin / leuprolide.
openFDA has a label for "Givinostat".
EMA register: MabCampath (alemtuzumab) Withdrawn, 2001-07-06.
EMA register: Xagrid (anagrelide) Authorised, 2004-11-15.
EMA register: Emend (aprepitant) Authorised, 2003-11-11.
EMA register: Targretin (bexarotene) Authorised, 2001-03-29.
EMA register: Busilvex (busulfan) Withdrawn, 2003-07-09.
EMA register: Xeloda (capecitabine) Authorised, 2001-02-02.
EMA register: Tabrecta (capmatinib) Authorised, 2022-06-20.
EMA register: Carmustine medac (previously Carmustine Obvius) (carmustine) Authorised, 2018-07-18.
EMA register: Korjuny (catumaxomab) Authorised, 2025-02-10.
EMA register: Evoltra (clofarabine) Authorised, 2006-05-29.
EMA register: DepoCyte (cytarabine) Withdrawn, 2001-07-11.
EMA register: Tafinlar (dabrafenib) Authorised, 2013-08-26.
EMA register: Aranesp (darbepoetin alfa) Authorised, 2001-06-08.
EMA register: Vyxeos liposomal (previously Vyxeos) (daunorubicin;cytarabine) Authorised, 2018-08-23.
Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Localised anal squamous cell carcinoma.
Published in Cancer Cell on 16 September 2026; matched the OnCo record for Adebrelimab.
Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Trastuzumab rezetecan.
Published in Nature on 15 September 2026; matched the OnCo record for Erythropoietin receptor.
Published in Nat Med on 15 September 2026; matched the OnCo record for GFH375.
Published in Nat Cancer on 14 September 2026; matched the OnCo record for FOLFIRI.
Published in J Clin Oncol on 14 September 2026; matched the OnCo record for Afatinib.
Published in N Engl J Med on 12 September 2026; matched the OnCo record for YL201.
On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Accelerated approval (Etcamah).
On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.: dolutegravir.
On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Subcutaneous formulation (PALOMA-3).
On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC).
Programme deprioritised after regulatory feedback on Duravelo-2 design.
For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State: Arm A: Lazertinib With Amivantamab SC-CF 206 micrograms per milliliters (mcg/ml) versus Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion 144 micrograms per milliliters (mcg/ml).
Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator: BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone 25.99 months, hazard ratio 0.515.
Overall Survival (OS): Nofazinlimab + Lenvatinib 21.6 months versus Placebo + Lenvatinib 18.5 months.
Major Pathological Response (MPR) - IASLC Method: Osimertinib + Chemo 25.6 % versus Osimertinib 24.8 % versus Placebo + Chemo 1.7 %.
Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale: Nivo + Rela FDC SC 4.141 ug/ml versus Nivo + Rela FDC IV 3.901 ug/ml.
Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale: Nivolumab SC 77.373 μg/ml versus Nivolumab IV 36.875 μg/ml versus Nivo SC Process C 75.504 μg/ml versus Nivo SC Process D 75.596 μg/ml.
Progression Free Survival (PFS): Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 8.4 months versus Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 4.4 months, hazard ratio 0.43.
Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis): Asciminib 16 participants versus Nilotinib 34 participants, hazard ratio 0.45.
Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12): Treatment 23.08 % versus Control 13.33 %.
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Overall survival 17.7 vs 18.0 months (HR 0.92, p 0.32) overall and 20.4 vs 20.4 months (HR 1.05) in PIK3CA/AKT1/PTEN-altered tumours; PFS 5.6 vs 5.1 months (HR 0.72).
Co-primary endpoints including OS met (July 2026); numbers pending.
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.
Stopped early; primary endpoint not met.
Overall Survival (OS) (Arm A Versus Arm C): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 months versus Docetaxel (Arm C) 11.3 months, hazard ratio 0.85.
Marketing authorisation withdrawn in the European Union in 2026: Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons).
Marketing authorisation withdrawn in the European Union in 2025: Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025.
Marketing authorisation withdrawn in the European Union in 2025: MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing).
A 2025 EU regulation that gives patients electronic access to their health records across the Union and creates national bodies that can grant researchers, regulators and companies permission to use anonymised or pseudonymised health data, phased in over the rest of the decade.
Everything above is read at build time from snapshots and records already in the repository; nothing is fetched when the page is viewed. Where each kind comes from and how often its source refreshes, from the workflow schedules in .github/workflows:
FDA Oncology Center of Excellence approval notifications (public/fda/recent.json), dated approvals recorded on product pages, and European Commission authorisations from the regional approvals table with an EPAR or regulator link.
Refresh: FDA feed Wednesdays 06:07 UTC (refresh-fda.yml); EU rows checked against the EMA register Wednesdays 06:37 UTC (refresh-regional.yml); product pages by hand.
Dated withdrawals recorded on product pages and withdrawn EU authorisations in the regional approvals table, each with a source link.
Refresh: Same schedule as approvals.
Trials in the corpus with a reported year and structured outcomes, linked to the primary paper, sponsor release or registry entry the outcome cites.
Refresh: Curated by hand; ClinicalTrials.gov status refreshed Mondays 06:17 UTC (refresh-trials.yml).
The newest Europe PMC matches for every product, target, cancer and technology (public/papers), journal versions of tracked preprints, and papers the roadmap watch found for landmark trials. One entry per DOI, however many records it matched.
Refresh: Literature snapshot Tuesdays 05:41 UTC (refresh-papers.yml); roadmap watch Thursdays 05:29 UTC (roadmap-watch.yml).
bioRxiv, medRxiv, Research Square and other preprints of the last 90 days that match a target, product or technology query (public/preprints). Not peer reviewed.
Refresh: Wednesdays 06:17 UTC (refresh-preprints.yml).
Statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made, each linked to its primary text.
Refresh: Curated by hand; new instruments are added when they are enacted.
Changes the nightly bot proposes for the corpus from the FDA feed, the EMA register and registry status changes (public/proposals/latest.json). Proposals, not facts: each waits for a human to apply it.
Refresh: Daily 03:23 UTC (propose.yml).
OnCo's own weekly issue: what changed, regulatory events, upcoming readouts and what the journals published.
Refresh: Mondays 07:31 UTC (newsletter.yml); the archive is rebuilt with every deploy.
Dates are shown at the precision the source gives: a year-only law or authorisation is grouped under its year, never given a day. Papers are matched to records by their literature queries, so a code or a common word can pull in an unrelated paper; the record chips tell you what matched. Not medical advice.